Novel treatment strategy of targeting epigenetic dysregulation in pancreatic neuroendocrine tumors

Zhu, Clara; Sandilos, Georgianna; Williamson, John; Emery, Robert; Platoff, Rebecca; Joneja, Upasana; Acharya, Nimish K.; Lin, Alex T.L.; Badach, Jeremy; Zilberman, Brian; Madžo, Jozef; Jelı́nek, Jaroslav; Zhang, Ping; Hong, Young Ki

doi:10.1016/j.surg.2022.12.008

Cited by 2 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, combination therapies that concurrently enhance SSTR expression using HDACis and target SSTRs may demonstrate enhanced efficacy compared to individual therapies [17] (also refer to Section 3.2). Additionally, our laboratory has previously demonstrated that a combination of 5-azacytidine and chemotherapy can effectively reduce cell proliferation, activate silenced tumor suppressor genes, and diminish tumors in vivo [305].…”

Section: Future Directions For Epigenetic Research and Clinical Appli...mentioning

confidence: 99%

Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation

Saleh,

Moccia,

Ladd

et al. 2024

IJMS

Self Cite

View full text Add to dashboard Cite

Pancreatic neuroendocrine tumors (PNETs) are characterized by dysregulated signaling pathways that are crucial for tumor formation and progression. The efficacy of traditional therapies is limited, particularly in the treatment of PNETs at an advanced stage. Epigenetic alterations profoundly impact the activity of signaling pathways in cancer development, offering potential opportunities for drug development. There is currently a lack of extensive research on epigenetic regulation in PNETs. To fill this gap, we first summarize major signaling events that are involved in PNET development. Then, we discuss the epigenetic regulation of these signaling pathways in the context of both PNETs and commonly occurring—and therefore more extensively studied—malignancies. Finally, we will offer a perspective on the future research direction of the PNET epigenome and its potential applications in patient care.

show abstract

Section: Future Directions For Epigenetic Research and Clinical Appli...mentioning

confidence: 99%

Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation

Saleh,

Moccia,

Ladd

et al. 2024

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation

Saleh,

Moccia,

Ladd

et al. 2023

Preprint

View full text Add to dashboard Cite

Pancreatic neuroendocrine tumors (PNETs) are characterized by dysregulated signaling pathways that are crucial for tumor formation and progression. The efficacy of traditional therapies is limited, particularly in treatment of PNETs at advanced stage. Epigenetic alterations profoundly impact the activity of signaling pathways in cancer development, offering potential opportunities for drug development. There is currently a lack of extensive research on epigenetic regulation in PNETs. To fill this gap, we first summarize major signaling events which are involved in PNET development. Then, we discuss the epigenetic regulation of these signaling pathways in the context of both PNET and commonly occurring, and therefore more extensively studied, malignancies. Finally, we will offer perspective on the future research direction of PNET epigenome and its potential applications in patient care.

show abstract

Novel treatment strategy of targeting epigenetic dysregulation in pancreatic neuroendocrine tumors

Cited by 2 publications

References 23 publications

Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation

Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation

Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation

Contact Info

Product

Resources

About